Cargando…

Purification of modified vaccinia virus Ankara from suspension cell culture

Detalles Bibliográficos
Autores principales:	Jordan, Ingo, Weimer, Diana, Iarusso, Stefan, Bernhardt, Holger, Lohr, Verena, Sandig, Volker
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685402/ http://dx.doi.org/10.1186/1753-6561-9-S9-O13

Ejemplares similares

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
por: Jordan, Ingo, et al.
Publicado: (2013)

A Genotype of Modified Vaccinia Ankara (MVA) that Facilitates Replication in Suspension Cultures in Chemically Defined Medium
por: Jordan, Ingo, et al.
Publicado: (2013)

Cell lines from the Egyptian fruit bat are permissive for modified vaccinia Ankara
por: Jordan, Ingo, et al.
Publicado: (2009)

A novel genotype of MVA that efficiently replicates in single cell suspensions
por: Jordan, Ingo, et al.
Publicado: (2013)

Vaccination with recombinant modified vaccinia virus Ankara prevents the onset of intestinal allergy in mice
por: Bohnen, C, et al.
Publicado: (2013)

A Deleted Deletion Site in a New Vector Strain and Exceptional Genomic Stability of Plaque-Purified Modified Vaccinia Ankara (MVA)
por: Jordan, Ingo, et al.
Publicado: (2019)

Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles
por: Goepfert, P, et al.
Publicado: (2012)

OA02-06 LB. Recombinant modified Vaccinia virus ankara expressing HIV-1 genes activates NK subset capable of controlling HIN infection in vitro
por: Cummings, J, et al.
Publicado: (2009)

OA04-03. Characterization of cell-mediated immune responses generated by recombinant modified vaccinia Ankara (rMVA)-HIV-1 in a phase I vaccine trial
por: Currier, JR, et al.
Publicado: (2009)

OA04-02. Strong HIV-specific CD4 and CD8 T-lymphocyte proliferation in HIV-1 DNA prime/modified vaccinia virus Ankara (MVA) heterologous boost vaccinees
por: Nilsson, C, et al.
Publicado: (2009)

Production of Modified Vaccinia Ankara Virus by Intensified Cell Cultures: A Comparison of Platform Technologies for Viral Vector Production
por: Gränicher, Gwendal, et al.
Publicado: (2020)

Modified Vaccinia Virus Ankara Exerts Potent Immune Modulatory Activities in a Murine Model
por: Nörder, Miriam, et al.
Publicado: (2010)

Live attenuated influenza viruses produced in a suspension process with avian AGE1.CR.pIX cells
por: Lohr, Verena, et al.
Publicado: (2012)

Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?
por: Okeke, Malachy I., et al.
Publicado: (2017)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
por: Orlova, Olga Vladimirovna, et al.
Publicado: (2022)

Modified vaccinia Ankara–Bavarian Nordic vaccine against mpox in children
por: Turtle, Lance, et al.
Publicado: (2023)

Efficient and stable production of Modified Vaccinia Ankara virus in two-stage semi-continuous and in continuous stirred tank cultivation systems
por: Tapia, Felipe, et al.
Publicado: (2017)

Modified Vaccinia virus Ankara but not vaccinia virus induces chemokine expression in cells of the monocyte/macrophage lineage
por: Lehmann, Michael H, et al.
Publicado: (2015)

Generation of interleukin-13 receptor alpha2 antigen expressing modified vaccinia ankara recombinant virus for potential cancer immunotherapy
por: Sato, Yuki, et al.
Publicado: (2014)

Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?
por: Drexler, Ingo, et al.
Publicado: (2004)

Shaping the tumor microenvironment with Modified Vaccinia Virus Ankara and TLR9 ligand
por: Préville, Xavier, et al.
Publicado: (2015)

A vital gene for modified vaccinia virus Ankara replication in human cells
por: Sutter, Gerd
Publicado: (2020)

Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets
por: Czub, Markus, et al.
Publicado: (2005)

Preferential targeting of conserved Gag regions after vaccination with a heterologous DNA prime Modified Vaccinia Ankara boost HIV vaccine regime
por: Bauer, A, et al.
Publicado: (2012)

Immune Requirements of Post-Exposure Immunization with Modified Vaccinia Ankara of Lethally Infected Mice
por: Lauterbach, Henning, et al.
Publicado: (2010)

Non-plaque-forming virions of Modified Vaccinia virus Ankara express viral genes
por: Lülf, Anna-Theresa, et al.
Publicado: (2016)

Modified vaccinia virus Ankara as a vaccine against feline coronavirus: immunogenicity and efficacy
por: Hebben, Matthias, et al.
Publicado: (2004)

Protective CD8+ T Cell Response Induced by Modified Vaccinia Virus Ankara Delivering Ebola Virus Nucleoprotein
por: Kupke, Alexandra, et al.
Publicado: (2022)

P19-52 LB. Assessing and restructuring foreign gene insertion sites for enhanced stability of modified Vaccinia virus ankara recombinants expressing HIV genes
por: Wyatt, L, et al.
Publicado: (2009)

Expanding the Repertoire of Modified Vaccinia Ankara-Based Vaccine Vectors via Genetic Complementation Strategies
por: Garber, David A., et al.
Publicado: (2009)

Tracking Modified Vaccinia Virus Ankara in the Chicken Embryo: In Vivo Tropism and Pathogenesis of Egg Infections
por: Langenmayer, Martin C., et al.
Publicado: (2018)

Optimising T cell (re)boosting strategies for adenoviral and modified vaccinia Ankara vaccine regimens in humans
por: Capone, Stefania, et al.
Publicado: (2020)

Assessment of Immunogenicity and Efficacy of a Zika Vaccine Using Modified Vaccinia Ankara Virus as Carriers
por: López-Camacho, César, et al.
Publicado: (2019)

Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development
por: Volz, A., et al.
Publicado: (2017)

Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus
por: García-Arriaza, Juan, et al.
Publicado: (2021)

Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE(®) against aerosolized rabbitpox virus in a rabbit model()
por: Garza, Nicole L., et al.
Publicado: (2009)

Cell-line screening and process development for a fusogenic oncolytic virus in small-scale suspension cultures
por: Göbel, Sven, et al.
Publicado: (2022)

Environmental Risk Assessment of Clinical Trials Involving Modified Vaccinia Virus Ankara (MVA)-Based Vectors
por: Goossens, Martine, et al.
Publicado: (2013)

Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity
por: Alharbi, Naif Khalaf, et al.
Publicado: (2015)

Cardiac Safety of Modified Vaccinia Ankara for Vaccination against Smallpox in a Young, Healthy Study Population
por: Zitzmann-Roth, Eva-Maria, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_pueni9lm9vi2kmaklqc4i97nd6